Nexalin Technology, Inc. NXL
Institutional shares held
484,211
0
calls
0
puts
Total value of holdings
$1.92M
$0
calls
$0
puts
Market Cap
$28.8M
7,279,960
Shares Out.
Institutional ownership
6.65%
# of Institutions
17
We take great care to ensure that the data presented and summarized in this overview for Nexalin Technology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NXL
View all-
Jim Simons Renaissance Technologies LLC | New York, Ny103KShares$407,4840.0% of portfolio
-
Geode Capital Management, LLC Boston, MA78.7KShares$311,6400.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il58.2KShares$230,4120.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE55.5KShares$219,6290.81% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA42.4KShares$167,8360.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA31.8KShares$125,8480.0% of portfolio
-
Virtu Financial LLC New York, NY23.4KShares$92,8500.0% of portfolio
-
Two Sigma Securities, LLC New York, NY23KShares$91,2580.0% of portfolio
-
Atria Wealth Solutions, Inc. New York, NY17.2KShares$68,2780.0% of portfolio
-
State Street Corp Boston, MA16.8KShares$66,5280.0% of portfolio
Latest Institutional Activity in NXL
Top Purchases
Top Sells
About NXL
Insider Transactions at NXL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 28
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
500
+0.34%
|
$1,000
$2.19 P/Share
|
|
Sep 30
2024
|
Ben Hu Director |
BUY
Grant, award, or other acquisition
|
Direct |
175,000
+33.94%
|
-
|
|
Sep 30
2024
|
Leslie Bernhard Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,838
+50.0%
|
-
|
|
Sep 23
2024
|
Marilyn Elson > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
700,000
+31.32%
|
-
|
|
Aug 13
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.67%
|
$0
$0.95 P/Share
|
|
Jun 28
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.68%
|
$1,000
$1.75 P/Share
|
|
Jun 18
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,619
+1.1%
|
$0
$0.71 P/Share
|
|
Jun 10
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+1.03%
|
$0
$0.64 P/Share
|
|
Sep 28
2022
|
Marilyn Elson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
9,500
+1.12%
|
$9,500
$1.12 P/Share
|
|
Sep 16
2022
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.74%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Mark White President/CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+0.86%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Rick Morad Director |
BUY
Open market or private purchase
|
Direct |
2,500
+2.26%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Alan Kazden Director |
BUY
Open market or private purchase
|
Indirect |
2,500
+2.73%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Marilyn Elson > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
36,000
+4.18%
|
$144,000
$4.15 P/Share
|
Last 12 Months Summary
Buy / Acquisition
932K
Shares
From
4
Insiders
| Grant, award, or other acquisition | 925K shares |
|---|---|
| Open market or private purchase | 7.12K shares |
Sell / Disposition
0
Shares
From
0
Insiders